- Headquarters
- Cambridge, Massachusetts
- Employees
- 11–50
- Founded
- 2001
- Business Model
- B2B
- Website
- infi.com
- Last Round
- Series AJun 2002
- Rounds
- 2
- Type
- Public
About
Infinity Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing immuno-oncology therapies. Its lead candidate, eganelisib (IPI-549), is a potentially first-in-class, oral, once-daily selective inhibitor of PI3K-gamma that reprograms tumor-associated macrophages (M2 macrophages) to perform anti-tumor functions, thereby reducing immune suppression and encouraging immune activation. The company ran Phase 2 trials including MARIO-275 in urothelial cancer and MARIO-3 in triple-negative breast cancer. Infinity was listed on Nasdaq under ticker INFI and filed for Chapter 11 bankruptcy in October 2023.
Summary
Infinity Pharmaceuticals is a Biotech company based in Cambridge, United States, founded in 2001. Its most recent funding was a Series A round in Jun 2002. Investors include Biotechnology Value Fund, Advent Venture Partners and Venrock.
Funding History
Jan 2020
Sign up to see all 3 events
Funding: Series B through Series A. Amounts, valuations, and investors where available.
Investors
Similar Companies
BeOne Medicines develops transformative oncology medicines through rigorous science, an accelerat...
Avenzo is a San Diego, CA-based biopharma company to in-license and develop the next generation o...
Novel bicyclic peptides and drug conjugates for cancer
One of the world's largest contract research organizations (CROs), providing end-to-end clinical ...
Your company? Embed this profile
Add the live badge to your site — it stays current as your funding data updates.
<a href="https://indexed.vc/companies/infinity-pharmaceuticals"><img src="https://indexed.vc/api/badge/company/infinity-pharmaceuticals" alt="Infinity Pharmaceuticals on Indexed.vc" width="260" height="76" /></a>